cabergoline

FDA Drug Profile — Cabergoline

cabergoline is listed in the FDA National Drug Code directory with 3 NDC codes, marketed under brand name including Cabergoline. Available dosage form: tablet.

Drug details

Generic Name
cabergoline
Brand Names
Cabergoline
Application Number
NDA020664
Sponsor
Mylan Pharmaceuticals Inc.
NDC Codes
3
Dosage Forms
TABLET
Routes
ORAL
Active Ingredients
CABERGOLINE

Indications and Usage

1 INDICATIONS AND USAGE CABERGOLINE is an ergot derivative indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas in adults. Limitations of Use Avoid use of CABERGOLINE for the inhibition or suppression of postpartum physiologic lactation because of the risk of serious adverse reactions [see Warnings and Precautions (5.4) ] . CABERGOLINE is an ergot derivative indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas in adults. ( 1 ) Limitations of Use Avoid use of CABERGOLINE for the inhibition or suppression of postpartum physiologic lactation because of the risk of serious adverse reactions. ( 5.4 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.